Dapagliflozin

Dapagliflozin

IUPAC name	(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
Other names	BMS-512148 (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol
Identifiers
CAS number	[461432-26-8]
SMILES	[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)c2cc(Cc3ccc(OCC)cc3)c(Cl)cc2
InChI	1/C21H25ClO6/c1-2-27- 15-6-3-12(4-7-15)9- 14-10-13(5-8-16(14)22)21- 20(26)19(25)18(24)17(11- 23)28-21/h3-8,10,17-21, 23-26H,2,9,11H2,1H3/t17-, 18-,19+,20-,21+/m1/s1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references

Dapagliflozin (rINN/USAN) is an experimental SGLT2 inhibitor being studied by Bristol-Myers Squibb as a potential treatment for type 1 and 2 diabetes.^[1]

[edit] References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10)

Biguanides	Metformin

Sulfonylureas	Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide

Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose

Thiazolidinediones (TZD)	Pioglitazone, Rivoglitazone^†, Rosiglitazone, Troglitazone^‡

Meglitinides	Nateglinide, Repaglinide, Mitiglinide

Dipeptidyl peptidase-4 (DPP-4) inhibitors	Alogliptin^†, Saxagliptin^†, Sitagliptin, Vildagliptin

Glucagon-like peptide-1 analog	Exenatide, Liraglutide^†, Albiglutide^†

Amylin analog	Pramlintide

Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera)

Dual PPAR agonists	Aleglitazar^†, Muraglitazar^§, Tesaglitazar^§

SGLT2 inhibitor	Dapagliflozin^†, Remogliflozin^†, Sergliflozin^†

^†Undergoing clinical trials. ^‡ Withdrawn from market. ^§Development halted.